Despite the success of gene-modified cell therapies and the approval of CAR-T therapeutics in recent years, manufacturing of cell-based therapeutics still remains challenging and expensive due to the high variability and mostly manual processes, which drive up cost of goods(COGs). In order to overcome these challenges, Sartorius offers solutions for CAR-T process development to implement process control, automation, and through put as well as to deliver process understanding in order to ultimately develop a robust manufacturing process.
In this webinar, Julia Hupfield will present data on how T-cell expansion can be easily established in stirred-tank bioreactors using the Ambr®15 Cell Culture for early process development. The Ambr15 in combination with DoE provides the capability to screen and optimize process parameters at the small scale and with high throughput operation in a time- and cost- efficient manner. The critical process parameters identified can then be used to define process settings at larger scale.